These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 1942755)
21. The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies. Weinberg MS R I Med; 1995 Mar; 78(3):78-81. PubMed ID: 7734758 [No Abstract] [Full Text] [Related]
24. Improvement in current approaches to lipid lowering. Ansell BJ Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952 [No Abstract] [Full Text] [Related]
25. A vote of no confidence in the precision of the estimated cost-effectiveness of lipid lowering. Wilcock M Br J Gen Pract; 2000 Nov; 50(460):917-8. PubMed ID: 11141882 [No Abstract] [Full Text] [Related]
27. [Fliformine effects on blood lipid spectrum and lipid peroxidation in obese patients]. Ageeva VV; Krasil'nikova EI; Zubina IM; Shliakhto EV Klin Med (Mosk); 2000; 78(10):46-9. PubMed ID: 11220901 [TBL] [Abstract][Full Text] [Related]
28. [Hyperlipemia and pancreatitis]. Carrillo Penso N; Carrasquero O; Medina JA G E N; 1981; 35(1-2):15-27. PubMed ID: 6816659 [No Abstract] [Full Text] [Related]
29. Improving lipid goal attainment: is it enough? Gotto AM Circulation; 2009 Jul; 120(1):3-5. PubMed ID: 19546383 [No Abstract] [Full Text] [Related]
30. Common obstacles in lipid management. Elpers M Crit Care Nurs Clin North Am; 2008 Sep; 20(3):287-95. PubMed ID: 18644511 [TBL] [Abstract][Full Text] [Related]
31. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis]. Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580 [TBL] [Abstract][Full Text] [Related]
32. [Pharmacology of hypolipidemic agents]. Féry F; Balasse EO Rev Med Brux; 1997 Feb; 18(1):26-31. PubMed ID: 9132914 [TBL] [Abstract][Full Text] [Related]
33. [Guidelines for lipid-lowering therapy. Results of the 2d Consensus Conference of the European Atherosclerosis Society. Press conference. London, 6 May 1988]. Fortschr Med Suppl; 1988; 46():1-22. PubMed ID: 2905324 [No Abstract] [Full Text] [Related]
34. [Cost-benefit analysis of the therapy of lipid metabolism disorders]. Karádi I Orv Hetil; 1996 May; 137(21):1164. PubMed ID: 8757110 [No Abstract] [Full Text] [Related]
36. Management of hyperlipidaemia: postscript. Sum CF; Tan CE; Chew LS Singapore Med J; 1995 Oct; 36(5):538. PubMed ID: 8882543 [No Abstract] [Full Text] [Related]
37. Does lipid-lowering therapy slow progression of chronic kidney disease? Wheeler DC Am J Kidney Dis; 2004 Nov; 44(5):917-20. PubMed ID: 15492960 [No Abstract] [Full Text] [Related]
38. Lipid-lowering drugs: French prescribers under pressure. Prescrire Int; 2002 Oct; 11(61):158. PubMed ID: 12378750 [No Abstract] [Full Text] [Related]
39. [Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia]. Arteaga A; Foradori A; Eyzaguirre J; Lira P; Vasquez A; Soto S; Alliende ME; Guzman L Rev Med Chil; 1970 Oct; 98(10):689-94. PubMed ID: 4927028 [No Abstract] [Full Text] [Related]
40. Drug therapy of the hyperlipidemias. Armstrong ML Iowa Med; 1985 Jan; 75(1):26-30. PubMed ID: 3967963 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]